News

Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma

Martin Dreyling
Martin Dreyling

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rĂ´les of other targeted agents.

Download this interview

Similar Interviews

  • Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
  • Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable,

  • Audio Journal of Oncology 13.2, February 2005
  • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Chemotherapy Foundation Symposium, November 10-13

  • Audio Journal of Hematologic Malignancy Special Edition 2005
  • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions,

    Post a comment

    Subscribe to Audio Medica Podcast